The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

In 2022, pharmaceutical giant Pfizer (NYSE: PFE) became the first healthcare company to generate $100 billion in annual sales ...

In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Pfizer (PFE – Research Report). The company’s shares ...

We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance.

For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor with much lower safety risks compared with a direct oral anticoagulant (DOAC), ...

Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders.

The study of more than two million veterans with diabetes details GLP-1 RA use relating to 175 outcomes; without ...

2025 is set to be a game-changing year for cancer research, with cutting-edge therapies and technologies driving unprecedented progress in oncology.

Eldercide, as, as Margaret Morganroth Gullette describes in her recent book “American Eldercide: How It Happened, How to ...

In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.

It's been about five years since the first case of COVID-19 was confirmed in Australia. This is what Australia living through "unprecedented times" looks like in numbers.

The Pharmaceutical Technology Excellence Awards winners have been announced! Download our full 50+ page report to find out ...